Abstract P3-06-18: Comprehensive genomic profiling of carcinosarcomas of the breast

Autor: LM Gay, JA Elvin, J-A Vergilio, JK Killian, S Ramkissoon, E Severson, S Daniel, A Hammerich, E Sokol, G Frampton, J Chung, S Trabucco, S Ali, P Reddy, AB Schrock, VA Miller, JS Ross

Publikováno v: Cancer Research. 79:P3-06

Background: Carcinosarcomas of the breast (BCSC) are exceptionally rare and the underlying genomic drivers are still being elucidated. Comprehensive genomic profiling (CGP) determines the tumor mutation burden (TMB) and identifies all four classes of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d0364cff9d039f3fba3948878c918ee
https://doi.org/10.1158/1538-7445.sabcs18-p3-06-18

Abstract P5-21-20: Integrating comprehensive genomic profiling with treatment decisions – Experience gained while treating 139 advanced breast carcinomas

Autor: R Mahtani, LM Gay, J Chung, R Hartmaier, E Sokol, JA Elvin, S Daniel, S Ramkissoon, E Severson, J Suh, J-A Vergilio, PJ Stephens, JS Ross

Publikováno v: Cancer Research. 78:P5-21

Background: Comprehensive Genomic Profiling (CGP) using next-generation sequencing (NGS) technology can provide insight into potentially clinically relevant genomic alterations (CRGA) within a patient's breast cancer. For example, HER2 amplification

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e99220aa225a68dcb4987933ba04950
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-20

Abstract P1-05-08: Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Autor: JS Ross, LM Gay, JA Elvin, J Suh, J-A Vergilio, S Ramkissoon, A Schrock, S Ali, VA Miller, PJ Stephens

Publikováno v: Cancer Research. 77:P1-05

Background: Breast carcinomas (BC) are commonly classified into 4 subtypes based on hormone receptor expression: basal, luminal A, luminal B, and HER2 overexpressed. Comprehensive genomic profiling (CGP) reveals targetable genomic alterations (GA) ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d61bdfc0debeec83178459226bcb3ff9
https://doi.org/10.1158/1538-7445.sabcs16-p1-05-08

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.

Autor: Turner JA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Van Gulick RJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Robinson WA; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Mughal T; Division of Hematology-Oncology, Tufts University Cancer Center, Boston, Massachusetts, USA., Tobin RP; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., MacBeth ML; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Holman B; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Classon A; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Bagby SM; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Yacob BW; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Hartman SJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Silverman I; Ignyta, Inc., San Diego, California, USA., Vorwald VM; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gorden N; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gonzalez R; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gay LM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Benson A; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA.; Department of Pathology, Upstate Medical University, Syracuse, New York, USA., Pitts TM; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Rioth MJ; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Lewis KD; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Medina T; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., McCarter MD; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Gonzalez R; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Couts KL; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Center for Rare Melanomas, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Nov 15; Vol. 155 (10), pp. 1792-1807. Date of Electronic Publication: 2024 Jul 12.

Targeted genomic analysis of 364 adrenocortical carcinomas.

Autor: Pozdeyev N; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA.; Division of Biomedical Informatics & Personalized Medicine, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA., Fishbein L; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA.; Division of Biomedical Informatics & Personalized Medicine, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA., Gay LM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Sokol ES; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Hartmaier R; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA.; Departments of Pathology and Urology, Upstate Medical University, Syracuse, New York, USA., Darabi S; Hoag Family Center Institute, Newport Beach, California, USA., Demeure MJ; Hoag Family Center Institute, Newport Beach, California, USA.; Translational Genomics Research Institute, Phoenix, Arizona, USA., Kar A; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA., Foust LJ; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA., Koc K; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA., Bowles DW; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Leong S; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Wierman ME; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA.; Research Service Veterans Affairs Medical Center, Aurora, Colorado, USA., Kiseljak-Vassiliades K; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA.; Research Service Veterans Affairs Medical Center, Aurora, Colorado, USA.

Publikováno v: Endocrine-related cancer [Endocr Relat Cancer] 2021 Aug 16; Vol. 28 (10), pp. 671-681. Date of Electronic Publication: 2021 Aug 16.